JS004

Phase 2Small molecule

SShanghai Pulmonary Hospital, Shanghai, China

JS004 is one of 128 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

127

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerNot yet recruiting

Small Cell Lung CancerNot yet recruiting

Pancreatic CancerNot yet recruiting

ToripalimabRecruiting

Non-Small Cell Lung CancerPhase 2

Not yet recruiting

Small Cell Lung CancerPhase 2

Not yet recruiting

Pancreatic CancerPhase 2

Not yet recruiting

ToripalimabPhase 2

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Tuoyi

SSun Yat-sen University

Phase 3

8 2

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Phase 3

3 3

Nanocrystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

1 4

JS004

SShanghai Pulmonary Hospital, Shanghai, China

Phase 2

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Toripalimab

NCT06690697

Q2 2027

Phase 1/2Not yet recruiting

Pancreatic Cancer

NCT06370754

Q3 2030

Phase 2Not yet recruiting

Non-Small Cell Lung Cancer

NCT05891080

Phase 2Not yet recruiting

Small Cell Lung Cancer

NCT06648200

Q1 2032

Phase 2Recruiting

Small Cell Lung Cancer

NCT06256237

Clinical

Trials by Indication[1]

Small Cell Lung Cancer2 trials

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06256237·30 enrolled

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06648200·100 enrolled

Toripalimab1 trial

Combination of Toripalimab and JS004 Therapy for ccRCC

Recruiting·FFudan University·Phase 2·NCT06690697·80 enrolled

Non-Small Cell Lung Cancer1 trial

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT05891080·124 enrolled

Pancreatic Cancer1 trial

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

Not yet recruiting·FFudan University·Phase 1/2·NCT06370754·117 enrolled

Patients With Advanced Solid Tumors1 trial

A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

Terminated·SShanghai Junshi Bioscience Co., Ltd.·Phase 1·NCT05427396·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for JS004. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JS004 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JS004. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Pulmonary Hospital, Shanghai, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Pulmonary Hospital, Shanghai, China

JS004

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2030

Q1 2032

Trials by Indication[1]

Small Cell Lung Cancer2 trials

Toripalimab1 trial

Non-Small Cell Lung Cancer1 trial

Pancreatic Cancer1 trial

Patients With Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News